PF-08653944

Berobenatide is Pfizer's late entry into the GLP-1 obesity race, a once-weekly or once-monthly peptide acquired from Metsera in a late-2025 deal totaling up to roughly $7.2B after a bidding war with Novo Nordisk [1][2]. The Phase 2b VESPER-1 study already reported mean placebo-subtracted weight loss of 14.1 percent at 28 weeks with individual responses up to 26.5 percent, which sets a credible floor for the Phase 3 program [12]. Phase 3 VESPER readouts across obesity, obesity plus type 2 diabetes, and obstructive sleep apnea are expected in 2027 [3][4][5][6]. If weight loss holds near Phase 2 levels and the monthly dosing option delivers, Pfizer gets a credible shot at a category where Novo and Lilly together booked roughly $45B in combined 2024 GLP-1 revenue [7][8].

Novel peptide compound (MET-097i, Pfizer code PF-08653944). Phase 3 across four VESPER trials under a single sponsor. No FDA designations have been disclosed, which is standard for an obesity asset in 2026 given the many approved options already on the market. The compound originated at Metsera as MET-097i, and Pfizer completed the Metsera acquisition on November 13, 2025 for $65.60 per share in cash plus a contingent value right of up to $20.65 per share (approximately $2.3B maximum in CVR payments on top of roughly $4.9B upfront) after outbidding Novo Nordisk in a protracted deal process [1][2][19]. Four Phase 3 trials are active: NCT07311850 (VESPER-3 flagship monotherapy, 3,578 patients, weekly dosing, fully enrolled) [3], NCT07400653 (obesity plus type 2 diabetes, 1,078 patients, fully enrolled) [4], NCT07595549 (monthly dosing in obesity, 954 patients, still recruiting) [5], and NCT07823608 (sleep apnea with CPAP, 258 patients, still recruiting) [6]. A Phase 2 combination trial of berobenatide with amylin analog PF-08653945 (Metsera code MET-233i, NCT07575932) is also running [9]. Topline primary readouts are not expected until 2027, with regulatory filings most plausible in 2028. The breadth of the Phase 3 program signals Pfizer intends to launch into multiple indications simultaneously if the data cooperate, mirroring the Lilly playbook where tirzepatide layered sleep apnea and other indications quickly after the initial Zepbound approval [10].

GLP-1 (glucagon-like peptide 1) is a gut hormone released after meals that tells the pancreas to secrete insulin, slows how fast the stomach empties, and acts on the brain to turn down appetite [11]. Drugs that activate the GLP-1 receptor cause substantial weight loss and improve blood sugar. The mechanism is as validated as any target in metabolic medicine: Novo's semaglutide franchise (Ozempic, Wegovy, Rybelsus) booked roughly $29B in 2024, and Lilly's tirzepatide (Zepbound, Mounjaro, a dual GLP-1 and GIP agonist) added roughly $16B in the same year [7][8]. Berobenatide's twist is biased agonism combined with a long half-life. The peptide uses a lipidated backbone engineered for ultra-long duration (supporting weekly and monthly dosing) and residues tuned to preferentially engage the cAMP arm of the GLP-1 receptor over the beta-arrestin arm. When a GLP-1 drug hits the receptor, the receptor can trigger two downstream arms: the cAMP arm, which does the useful work of insulin release, satiety signaling, and weight loss, and the beta-arrestin arm, which drives receptor internalization and is thought to contribute to the nausea and vomiting that push many patients off standard GLP-1s. A biased agonist that favors the cAMP arm should, in theory, deliver comparable weight loss with cleaner tolerability. Metsera's Phase 2b VESPER-1 trial (28 weeks, weekly dosing in obesity) reported mean placebo-subtracted weight loss of 14.1 percent at the 1.2 mg dose, with individual responses up to 26.5 percent and gastrointestinal adverse events described as mild to moderate and short-lived [12]. Whether the bias translates to measurably lower discontinuation at Phase 3 scale is the key unknown. The biology case is strong. Every new GLP-1 analog is now a tolerability and durability contest, not a target validation question.

VESPER-3 (NCT07311850) is the backbone: 3,578 adults with obesity or overweight, weekly subcutaneous berobenatide versus placebo, primary endpoint percent change in body weight [3]. The size supports claims against the real-world Wegovy and Zepbound benchmark of 15 to 22 percent weight loss. The sleep apnea trial (VESPER-OSA 1, NCT07823608) tests change in apnea-hypopnea index (AHI, the number of breathing interruptions per hour of sleep; 30 or more is severe) in 258 obese adults using CPAP, the same endpoint tirzepatide used to secure the SURMOUNT-OSA label expansion in late 2024 [6][13]. VESPER-M (NCT07595549, 954 patients, monthly dosing) is the strategically interesting trial because no approved GLP-1 offers monthly dosing and the compliance argument is strong if efficacy holds [5]. The T2D trial (NCT07400653, 1,078 patients) targets the dual obesity and diabetes population where tirzepatide dominates [4]. A Phase 2 combination with PF-08653945 (NCT07575932, 940 patients) tests whether adding an amylin agonist pushes weight loss into the 25 percent plus range that retatrutide and CagriSema are chasing [9]. Amylin is a second pancreatic hormone co-secreted with insulin that slows gastric emptying and suppresses glucagon. GLP-1 agonism primarily hits brain-level appetite signaling, while amylin agonism hits complementary gastric and glucose pathways, which is why GLP-1 plus amylin combinations are expected to stack weight-loss effects beyond either alone. Enrollment status splits cleanly: VESPER-3 and the T2D trial are already fully enrolled (active, not recruiting), while VESPER-OSA and VESPER-M are still recruiting. Primary endpoints are standard, trial sizing is appropriate, and the comparator choice (placebo rather than active GLP-1) is conservative. The missing piece is a head-to-head against semaglutide or tirzepatide. Pfizer has not publicly committed to or ruled out such a study for berobenatide, but payer uptake in a mature class will almost certainly require it eventually.

Our model estimates a 56% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 66%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual, larger-than-typical enrollment for this phase, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is low on absolute weight loss (Phase 2b already delivered 14.1 percent at 28 weeks) but high on relative differentiation at the 52-week Phase 3 timepoint. If berobenatide lands at 15 to 17 percent while tirzepatide produces 20 percent plus, approval is possible but commercial traction is not [10]. The biased-agonism hypothesis has not been confirmed at Phase 3 scale for any GLP-1, so the cleaner-tolerability pitch remains a bet rather than a fact. Safety risk includes the standard class issues: pancreatitis, gallbladder disease, and the medullary thyroid cancer boxed warning carried by every drug in this class. Pfizer-specific execution risk is real given danuglipron and lotiglipron, though berobenatide was designed by Metsera's team rather than Pfizer's internal metabolic group [14][15]. Commercial risk is the dominant concern. By 2027 to 2028 the obesity market will have oral GLP-1s (Lilly's orforglipron), triple agonists (retatrutide from Lilly in Phase 3), amylin combinations (CagriSema from Novo), and generic erosion starting on semaglutide in several markets [16]. Payers are tightening coverage criteria across the category. Monthly dosing is a genuine differentiator, but only if weight loss matches weekly competitors, otherwise prescribers will stay with what already works. Peptide supply and manufacturing risk has eased since the 2024 shortages but is not fully resolved. On exclusivity, peptide GLP-1 analogs with lipidated backbones typically carry composition-of-matter patents extending into the early-to-mid 2030s; if berobenatide tracks that norm, Pfizer gets roughly 7 to 10 years of unencumbered commercial runway from a 2028 launch, though the exact patent horizon has not been publicly specified. The Metsera deal priced in success at up to roughly $7.2B of total consideration, so even a technical Phase 3 win may not generate meaningful upside unless the differentiation story proves out and the CVR-triggering milestones (combo Phase 3 start, monthly monotherapy approval, combo approval) are hit [1][2][19].

Worth watching. The reasons are commercial, not biological. GLP-1 is settled biology, the Phase 3 program is well-designed and already partially enrolled, Phase 2b delivered 14.1 percent placebo-subtracted weight loss, and the mechanism will almost certainly produce statistically significant Phase 3 weight loss. The data points to track are: whether Pfizer discloses or runs a head-to-head against semaglutide or tirzepatide (not currently announced), VESPER-OSA 1 interim data expected in 2026, and the Phase 2 combination with amylin analog PF-08653945 (MET-233i), which is Pfizer's real shot at a next-generation 25 percent plus weight-loss asset competitive with retatrutide and CagriSema [9]. The CVR milestone structure is particularly informative on how the counterparties priced success: of the up-to-$20.65 per-share CVR, $4.60 pays on Phase 3 initiation of the MET-097i plus MET-233i combination, $6.40 pays on FDA approval of monthly MET-097i monotherapy, and $9.65 pays on FDA approval of the monthly MET-097i plus MET-233i combination [19]. The combination asset and the monthly dosing form, not the weekly monotherapy, are what the deal is really valuing. Pfizer paid roughly $4.9B upfront plus up to $2.3B in CVRs for Metsera in the acquisition that closed November 13, 2025 [1][2][19]. With $62.6B in 2024 revenue the company can afford the deal, but the obesity portfolio needs berobenatide to work after the danuglipron and lotiglipron washouts [17]. Check back for VESPER-OSA 1 interim data, VESPER-M monthly dosing readout, and any disclosed head-to-head plans. The acquisition economics make this a defining program for Pfizer's R&D strategy under current leadership, not just another pipeline bet.